Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinio KM, Jaggi P, Oster ME, Zackai SP, Gillen J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan MA, Alharash H, Doymaz S, Clouser KN, Giuliano JS, Gupta A, Parker RM, Maddux AB, Havalad V, Ramsingh S, Bukulmez H, Bradford TT, Smith LS, Tenforde MW, Carroll CL, Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado Munoz A, Hobbs CV, Marohn KL, Halasa NB, Patel MM, Randolph AG. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. New England Journal Of Medicine 2020, 383: 334-346. PMID: 32598831, PMCID: PMC7346765, DOI: 10.1056/nejmoa2021680.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBetacoronavirusCenters for Disease Control and Prevention, U.S.ChildCoronavirus InfectionsCOVID-19Critical CareFemaleGlucocorticoidsHumansImmunoglobulins, IntravenousImmunomodulationInflammationLength of StayMaleMucocutaneous Lymph Node SyndromePandemicsPneumonia, ViralProspective StudiesRespiration, ArtificialRetrospective StudiesSARS-CoV-2Systemic Inflammatory Response SyndromeUnited StatesConceptsMultisystem inflammatory syndromeInflammatory syndromeSARS-CoV-2Antibody testingSevere acute respiratory syndrome coronavirus 2Kawasaki disease-like featuresAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Coronary artery aneurysmsIntravenous immune globulinMultisystem organ involvementEvidence of infectionOrgan system involvementSyndrome coronavirus 2Reverse transcriptase-polymerase chain reactionCoronavirus disease 2019Life-threatening illnessPediatric health centersPublic health implicationsImmunomodulating therapiesVasoactive supportImmune globulinMedian durationMost patientsOrgan involvement